Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care (SCAVANCE)

AstraZeneca

Status: Terminated

Conditions: Acute Coronary Syndrome

Study type: Observational

Funder types: Industry

Identifiers

NCT01105325

NIS-CFR-CRE-2010/1

Details and patient eligibility

About

To study compliance with secondary prevention during the first months following discharge from the cardiac intensive care unit (CIC) of patients experiencing a first episode of acute coronary syndrome : quantitative compliance over 3 months with the two principal treatments of the prescription (a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®), using an electronic measure system ("intelligent blister" pack®);

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® -rosuvastatin is the most appropriate statin, in combination with a platelet aggregation inhibitor (Plavix®-clopidogrel)
• Patient giving his/her oral consent to participate in the study.
• Patient not previously treated by a lipid-lowering drug.

Exclusion criteria

• Patient with a known history of coronary heart disease.
• Patient whose treatment on discharge comprises only one of the two study treatments
• Patient participating or who has participated in the previous 3 months in a biomedical research study in cardiology.